樂觀
$33.09
情境價格
$16.630
+0.151 (+0.91%)收盤時
Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief.
Perrigo Company PLC is a good buy right now due to its current price of $15.06 being below the analyst target price of $15.25, suggesting room for growth. Additionally, the stock has shown a 5-day change of +5.61%, indicating positive momentum. However, investors should be cautious of the company's recent financial challenges, including a net income loss of $398.6 million in Q1 2026, which poses a risk to profitability.
JPMorgan
$15
2026-02-27
JPMorgan
2026-02-27
目標價
$15
Canaccord
$17
2026-02-27
Canaccord
2026-02-27
目標價
$17
JPMorgan
$18
2025-12-15
JPMorgan
2025-12-15
目標價
$18
Canaccord
$20
2025-11-06
Canaccord
2025-11-06
目標價
$20
JPMorgan
$20
2025-11-06
JPMorgan
2025-11-06
目標價
$20
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Perrigo Shares Surpass Analyst Target Price of $15.25

Perrigo to Participate in Barclays Global Consumer Conference

Perrigo Shares Surpass Analyst Target Price of $14.50

Perrigo Faces Financial Challenges Amid CEO Transition

Perrigo CEO Abruptly Departs Amid Weak Financial Performance
Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Perrigo Company PLC is a good buy right now due to its current price of $15.06 being below the analyst target price of $15.25, suggesting room for growth. Additionally, the stock has shown a 5-day change of +5.61%, indicating positive momentum. However, investors should be cautious of the company's recent financial challenges, including a net income loss of $398.6 million in Q1 2026, which poses a risk to profitability.
18 analysts cover PRGO: 6 rate it Buy, 11 Hold and 1 Sell. The average price target is 20.33.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。